• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Sanofi, Transgene form long-term collaboration for production of immunotherapy treatments

Sanofi, Transgene form long-term collaboration for production of immunotherapy treatments

March 25, 2013
CenterWatch Staff

Global healthcare company Sanofi and biopharmaceutical company Transgene have signed a collaboration agreement for the creation of a new state-of-the-art industrial platform dedicated to the production of immunotherapy products including Transgene's therapeutic products.

The platform will be realized on Genzyme Polyclonals site in Lyon, France, for an investment amount of roughly $13 million equally financed by Sanofi and Transgene. The platform will remain Sanofi's exclusive property.

Sanofi and Genzyme will act as Transgene's CMO to manufacture clinical and commercial batches of drug substance of Transgene's immunotherapy products, including its MVA1 therapeutic vaccines. Transgene will be a preferred customer of the commercial manufacturing platform for 15 years.

"Transgene is extremely pleased to announce this agreement with the Sanofi Group, as it combines the strong expertise of recognized experts and pioneers in the fields of gene therapy and vaccines," said Philippe Archinard, chairman and CEO of Transgene. "This collaboration will secure Transgene's commercial production over the long run, enabling us to focus our resources on development and marketing of our products."

Construction, qualification and validation of the manufacturing suite will start in the third quarter of 2013 and should be completed in 2015. First batches of commercial grade products from the suite are expected in 2015. Transgene expects to file its first BLA2 in 2016.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

  • SurveywBlueBackground-360x240.png

    Mid-Study Updates Delay Trials At Least a Month, CSDD Report Finds

  • Real-TimeData-360x240.png

    Real-Time Data Helped Sponsors Respond to Sites’ Needs During the Pandemic

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing